Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 13/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | HAO2 | Q9NYQ3 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27854218 | 0.89 | HCRTR1 (0.52) | HCRTR1HCRTR2PTGS2 | |
| SCHEMBL268643 | 0.87 | KDM4E (0.49) | HCRTR1HCRTR2ALOX5 | |
| SCHEMBL1257080 | 0.86 | HCRTR1 (0.50) | HCRTR1HCRTR2PTGS2 | |
| SCHEMBL80459 | 0.85 | ALOX5 (0.61) | HCRTR1HCRTR2PTGS2ALOX5 | |
| SCHEMBL269233 | 0.84 | SMN1; SMN2 (0.51) | HCRTR1HCRTR2PTGS2ALOX5 | |
| SCHEMBL925813 | 0.84 | PTGS2 (0.49) | HCRTR1HCRTR2PTGS2ALOX5 | |
| SCHEMBL1398894 | 0.84 | HCRTR1 (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL20780901 | 0.84 | PTGS2 (0.47) | HCRTR1HCRTR2PTGS2ALOX5 | |
| SCHEMBL269217 | 0.83 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL270041 | 0.83 | HCRTR1 (0.44) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101778846-A | 1, 2-diamido-ethylene derivatives as orexin antagonists | ACTELION PHARMACEUTICALS LTD | 2010-07-14 | — | — | CN | claimed |
| EP-2188282-A2 | 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-05-26 | — | — | EP | claimed |
| WO-2009022311-A2 | 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-19 | — | — | WO | claimed |
| US-7468367-B2 | Ethylene diamine derivatives and their use as orexin-receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-12-23 | — | — | US | claimed |
| EP-1456203-B1 | ETHYLENE DIAMINE DERIVATIVES AND THEIR USE AS OREXIN-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2008-08-20 | — | — | EP | claimed |
| US-20050159421-A1 | Ethylene diamine derivatives and their use as orexin-receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 2005-07-21 | — | — | US | claimed |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | disclosed |
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2024-09-10 | — | — | US | disclosed |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-04 | — | — | US | disclosed |
| CN-111315734-B | Substituted 2-azabicyclo [3.1.1] heptane and 2-azabicyclo [3.2.1] octane derivatives as orexin receptor antagonists | 克罗诺斯治疗有限公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4272824-A2 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-11-08 | — | — | EP | disclosed |
| EP-4272824-A2 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-11-08 | — | — | EP | disclosed |
| WO-2003051873-A1 | PIPERAZINE COMPOUNDS AND THEIR PHAMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051872-A1 | ETHYLENE DIAMINE DERIVATIVES AND THEIR USE AS OREXIN-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003002559-A2 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002561-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-01-09 | — | — | WO | disclosed |
| WO-2002090355-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002089800-A2 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002044172-A1 | MORPHOLINE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159421-A1 | Ethylene diamine derivatives and their use as orexin-receptor antagonists | HCRTR2, HCRTR1, GRPR | HCRTR1 2/4885HCRTR2 1/4885PTGS2 2253/4885 |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885PTGS2 1820/4885 |
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | HCRTR1 2/4885HCRTR2 1/4885PTGS2 1184/4885 |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885PTGS2 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.